Live Breaking News & Updates on Rare Disease Designation

Stay updated with breaking news from Rare disease designation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

PANTHERx® Rare Pharmacy Wins Sixth Patient Choice Award

/PRNewswire/ For a sixth time, PANTHERx Rare has been recognized as the winner of the annual Independent Specialty Pharmacy Patient Choice Award™. Since. ....

United States , Richard Faris , Rob Snyder , Insights Technology , Zitter Insights Specialty Pharmacy Patient Satisfaction , Managed Markets Insights , Patient Choice Award , Choice Award , Rare Chief Executive Officer Rob , Rare Disease Designation , Rare Disease Distinction , Pantherx Rare Pharmacy ,

Team Arnav Foundation Partners with OS Therapies Supporting the Phase IIb Trial of OST-HER2 (Listeria monocytogenes) in Recurred, Resected Osteosarcoma

/PRNewswire/ OS Therapies, a research and clinical-stage biopharmaceutical company and Team Arnav Foundation, a non-profit 501c3 organization focused on. ....

Paul Romness , Dhruv Krishna , Team Arnav Foundation , Founder Of Team Arnav Foundation , Team Arnav , Os Therapies Inc , Arnav Foundation , Clinical Trial , Resected Osteosarcoma , Pediatric Osteosarcoma Cancer , Overall Survival , Rare Disease Designation , Orphan Designations , Break Through Designation , Os Therapies ,

U.S. FDA approves first treatment option for generalized pustular psoriasis flares in adults

Press release content from Business Wire. The AP news staff was not involved in its creation. ....

New York , United States , Rheinland Pfalz , Petra Kienle , Carinne Brouillon , Mark Lebwohl , Ericj Waldman Department Of Dermatology , Icahn School Of Medicine At Mount Sinai , Corporate Communications , Drug Administration , European Medicines Agency , Boehringer Ingelheim , Clinical Therapeutics , Icahn School , Mount Sinai , Managing Directors , Human Pharma , Breakthrough Therapy Designation , Priority Review , Orphan Drug Designation , Rare Disease Designation , Business Wire ,

Boehringer Ingelheim receives FDA approval for GPP flares therapy

Boehringer Ingelheim has received the US FDA approval for its spesolimab, to treat adult patients with generalized pustular psoriasis (GPP) flares. ....

Carinne Brouillon , Ingelheim Managing Directors , Orphan Drug Designation , Priority Review , Rare Disease Designation , Breakthrough Therapy Designation ,

Boehringer Ingelheim: U.S. FDA approves first treatment option for generalized pustular psoriasis flares in adults

Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares After ....

New York , United States , Petra Kienle , Carinne Brouillon , Mark Lebwohl , Ericj Waldman Department Of Dermatology , Icahn School Of Medicine At Mount Sinai , Corporate Communications , European Medicines Agency , Boehringer Ingelheim , Drug Administration , Clinical Therapeutics , Icahn School , Mount Sinai , Managing Directors , Human Pharma , Breakthrough Therapy Designation , Priority Review , Orphan Drug Designation , Rare Disease Designation ,